The agency has cleared Otezla (apremilast) for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for an estimated eight ...
If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback